NCT02676596View on ClinicalTrials.gov

Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

January 31, 2015

Conditions
Hyperlipidemia
Interventions
DRUG

K-312 10 mg QD

DRUG

K-312 25 mg QD

DRUG

K-312 50 mg QD

DRUG

K-312 100 mg QD

DRUG

K-312 200 mg QD

DRUG

K-312 400 mg QD

OTHER

Placebo

Trial Locations (1)

Unknown

Glendale

Sponsors
All Listed Sponsors
lead

Kowa Research Institute, Inc.

INDUSTRY